NASDAQ · TRML
Healthcare · Biotechnology
$47.98
Up+$0.00 (+0.00%)
Updated Aug 19, 2026, 9:25 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
TRML does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning TRML.
TRML research
Company profile and research snapshot.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2025 | BMO Capital | Market Perform | — |
| Sep 11, 2025 | Piper Sandler | Neutral | — |
| Sep 10, 2025 | Guggenheim | Neutral | — |
| Sep 10, 2025 | Truist Securities | Hold | — |
| Sep 10, 2025 | Chardan Capital | Neutral | — |
No generated briefing is available yet.
globenewswire.com · Oct 28, 2025
Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline, have ceased trading on the Nasdaq Stock Market LLC and Tourmaline is now an indirect wholly owned subsidiary of Novartis.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TRML.
No results
No recent SID articles mention TRML.
